Axsome Therapeutics/$AXSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Health
Primary listing
Employees
846
Headquarters
Website
AXSM Metrics
BasicAdvanced
$5.2B
-
-$5.06
0.51
-
Price and volume
Market cap
$5.2B
Beta
0.51
52-week high
$139.13
52-week low
$75.56
Average daily volume
629K
Financial strength
Current ratio
1.569
Quick ratio
1.467
Long term debt to equity
198.366
Total debt to equity
294.619
Interest coverage (TTM)
-15.38%
Profitability
EBITDA (TTM)
-199.638
Gross margin (TTM)
91.48%
Net profit margin (TTM)
-49.88%
Operating margin (TTM)
-42.05%
Effective tax rate (TTM)
0.35%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-21.90%
Return on equity (TTM)
-280.68%
Valuation
Price to revenue (TTM)
10.238
Price to book
70.87
Price to tangible book (TTM)
299.35
Price to free cash flow (TTM)
-41.851
Free cash flow yield (TTM)
-2.39%
Free cash flow per share (TTM)
-2.484
Growth
Revenue change (TTM)
69.83%
Earnings per share change (TTM)
-22.25%
3-year revenue growth (CAGR)
282.87%
3-year earnings per share growth (CAGR)
8.88%
10-year earnings per share growth (CAGR)
24.64%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
AXSM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $5.2B as of August 13, 2025.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of August 13, 2025.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of August 13, 2025.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.